Canandaigua National Bank & Trust Co. Raises Holdings in Eli Lilly and Company $LLY

Canandaigua National Bank & Trust Co. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,992 shares of the company’s stock after acquiring an additional 833 shares during the quarter. Canandaigua National Bank & Trust Co.’s holdings in Eli Lilly and Company were worth $6,861,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company during the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at $29,000. Steph & Co. increased its holdings in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter worth about $31,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.2%

Shares of LLY opened at $1,042.06 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The stock has a market cap of $985.14 billion, a PE ratio of 50.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. The firm’s fifty day moving average is $951.95 and its two-hundred day moving average is $826.51. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wolfe Research lifted their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Guggenheim restated a “buy” rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Buy” and an average target price of $1,141.73.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.